BioStock: Alligator starts phase II and raises capital

To wrap up the third quarter 2021, Lund-based Alligator Bioscience announced that the first patient had been dosed in the phase II trial with drug candidate Mitazalimab in pancreatic cancer. Shortly after, the company also revealed its plans for a rights issue of 257 MSEK in order to be able to invest further in the clinical studies and the company’s assets.

Read the full article about Alligator Bioscience on biostock.se:

https://www.biostock.se/2021/10/alligator-starts-phase-ii-and-raises-capital/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/